Frequency of Use of a Recommended Medication for a Chronic Condition According to Presence of Competing Conditions among Community-living Persons in the U.S. Aged 65 and Older (N = 5815).

Abbreviations: COPD, chronic obstructive pulmonary disease; GERD/PUD, gastroesophageal reflux disease or peptic ulcer disease;aThe first chronic condition listed for a pair is the condition for which the medication is recommended by the national specialty organization guideline; the second chronic condition in a pair is the coexisting condition that may be worsened with the medication (i.e. competing condition).bThe numerator is the number of participants with the indicated condition who received the recommended medication. The denominator is the number of participants who had the indicated condition who also had the competing condition.cThe numerator is the number of participants with the indicated condition who received the recommended medication. The denominator is the number of participants who had the indicated condition but did not have the competing condition.dNumbers in brackets are the reference of the studies supporting the possible adverse effect of the medication class on the competing condition.

缩写说明：COPD为慢性阻塞性肺疾病（chronic obstructive pulmonary disease, COPD）；GERD/PUD为胃食管反流病或消化性溃疡病（gastroesophageal reflux disease or peptic ulcer disease, GERD/PUD）。
a. 每一组疾病配对中，首个列出的慢性疾病为国家专科组织指南推荐药物的适应证疾病；组内第二个慢性疾病为与该疾病共存、且可能因使用该推荐药物而病情加重的共病（即竞争性共病）。
b. 分子为确诊目标疾病且接受推荐药物治疗的受试者人数；分母为确诊目标疾病且同时合并竞争性共病的受试者人数。
c. 分子为确诊目标疾病且接受推荐药物治疗的受试者人数；分母为确诊目标疾病但未合并竞争性共病的受试者人数。
d. 方括号内的编号为支持该药物类别可能对竞争性共病产生不良影响的相关研究参考文献。